Company intelligence / Profile preview

Asieris Pharmaceuticals

Shanghai, Shanghai, Chinaprnewswire.com ↗

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Asieris has multiple late-stage clinical assets targeting genitourinary tumors and women’s health indications. Its lead program APL‑1202 for non-muscle invasive bladder cancer is in Phase III trials in China and the US. The company also develops photodynamic therapies such as APL‑1702 for cervical precancerous lesions now in Phase III trials. It has a broad pipeline including small molecules and antibody-drug conjugates with several programs advancing through preclinical to registrational stages.

Therapeutic areas: Infectious DiseasesWomen's HealthGastroenterologyOncology
Modalities: Small moleculeAntibody-drug conjugateChemical drugProteolysis-targeting chimera therapy (PROTAC)Photosensitizer
Industry: Biotech

Partnerships

Photocure ASA – global license agreement for Cevira® photodynamic therapy productSyneos Health – clinical trial collaboration partner

Beyond the preview

Go deeper on Asieris Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asieris Pharmaceuticals.

Explore the full profile